Organ-sparing strategies in the management of invasive bladder cancer.
Bladder cancer is the second most common genitourinary malignancy. Radical cystectomy and pelvic lymphadenectomy is the standard of care in the management of muscle-invasive bladder cancer. However, recently, bladder-preservation trials conducted by both single- and multi-institutional groups have gained momentum because of comparable survival and recurrence rates in select patients. While single-modality therapies have failed to provide adequate results, multimodal combination therapies consisting of a thorough transurethral resection with radiotherapy and concomitant chemotherapy have been promising. Careful patient selection, maximum transurethral resection of bladder tumor, cystoscopic evaluation of response with prompt salvage cystectomy for nonresponders and strict long-term follow-up for complete responders constitute the hallmarks of optimal bladder-preservation protocols. Advances in molecular-targeted therapy, chemotherapy and radiotherapy hold promise to improve survival and local control and decrease side effects and toxicity.
Yafi
Faysal A
FA
Department of Surgery (Urology), McGill University, Montreal, Quebec, Canada. faysal.yafi@mail.mcgill.ca
Cury
Fabio L
FL
Kassouf
Wassim
W
D000970:Antineoplastic Agents / Q000494:pharmacology; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods*; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D018579:Patient Selection; D016879:Salvage Therapy / Q000379:methods; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000628:therapy*
D000970:Antineoplastic Agents